澤璟製藥(688266.SH):注射用ZG005與含鉑化療方案聯用獲得藥物臨牀試驗批准通知書
格隆匯2月17日丨澤璟製藥(688266.SH)公佈,公司於近日收到國家藥品監督管理局核准簽發的《藥物臨牀試驗批准通知書》,注射用ZG005與含鉑化療方案聯合用於晚期膽道癌患者的臨牀試驗獲得批准。
ZG005擁有雙靶向阻斷PD-1和TIGIT的作用,既可以通過有效阻斷PD-1與其配體PD-L1的信號通路,進而促進T細胞的活化和增殖;又可以有效阻斷TIGIT與其配體PVR等的信號通路,促使PVR結合CD226產生共刺激激活信號,進而促進T細胞和NK細胞的活化和增殖,併產生兩個靶點被同時阻斷後的協同增強免疫系統殺傷腫瘤細胞的能力。
ZG005是重組人源化抗PD-1/TIGIT雙特異性抗體粉針劑,為創新型腫瘤免疫治療生物製品,註冊分類為1類,有望用於治療多種實體瘤。根據公開查詢,ZG005是全球率先進入臨牀研究的同靶點藥物之一,目前全球範圍內尚未有同類機制藥物獲批上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.